C-erbB3 Protein Expression in Ovarian Cancer

Overview

Journal Clin Mol Pathol

Specialty Molecular Biology

Date 1996 Aug 1

PMID 16696074

Citations 19

Authors

T Rajkumar

G W Stamp

C M Hughes

W J Gullick

Affiliations

Soon will be listed here.

Abstract

Aims-To study the prevalence of overexpression of c-erbB3 growth factor receptor in ovarian carcinomas and to analyse its relation to histological subtype, stage and grade of the tumours.Methods-Ninety eight ovarian carcinomas were evaluated immunohistochemically using the RTJ1 monoclonal antibody raised against a synthetic peptide, the sequence of which was derived from the cytoplasmic domain of the c-erbB3 protein.Results-Of the tumours, 16% (16/98) overexpressed c-erbB3 protein relative to normal ovarian epithelium, whereas 22% (22/98) were completely negative. There was a statistically significant association between overexpression and well differentiated grade.Conclusions-These findings suggest that c-erbB3 protein overexpression occurs in a significant proportion of ovarian cancers and is correlated with differentiation. Overexpression may merit further investigation as a potential prognostic indicator and as a target for new treatment.

Citing Articles

The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.

ONeill C, Sun K, Sundararaman S, Chang J, Glynn S Front Physiol. 2024; 15:1358850.

PMID: 38601214 PMC: 11004480. DOI: 10.3389/fphys.2024.1358850.

HER3 in cancer: from the bench to the bedside.

Gandullo-Sanchez L, Ocana A, Pandiella A J Exp Clin Cancer Res. 2022; 41(1):310.

PMID: 36271429 PMC: 9585794. DOI: 10.1186/s13046-022-02515-x.

Gastric Cancer Harboring an Mutation Treated with a Pyrotinib-Irinotecan Combo: A Case Study.

Ding K, Chen X, Li Y, Li W, Ye Y, He T Onco Targets Ther. 2021; 14:545-550.

PMID: 33500629 PMC: 7823137. DOI: 10.2147/OTT.S286024.

B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.

Kaumaya P Future Oncol. 2020; 16(23):1767-1791.

PMID: 32564612 PMC: 7426751. DOI: 10.2217/fon-2020-0224.

Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.

Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B Stem Cell Reports. 2020; 14(4):717-729.

PMID: 32243841 PMC: 7160357. DOI: 10.1016/j.stemcr.2020.03.004.

References

Foulkes W, Ragoussis J, Stamp G, Allan G, Trowsdale J . Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer. 1993; 67(3):551-9. PMC: 1968256. DOI: 10.1038/bjc.1993.101. View

Carraway 3rd K, Sliwkowski M, Akita R, Platko J, Guy P, Nuijens A . The erbB3 gene product is a receptor for heregulin. J Biol Chem. 1994; 269(19):14303-6. View

Lemoine N, Barnes D, Hollywood D, Hughes C, Smith P, Dublin E . Expression of the ERBB3 gene product in breast cancer. Br J Cancer. 1992; 66(6):1116-21. PMC: 1978009. DOI: 10.1038/bjc.1992.420. View

Issing W, Heppt W, Kastenbauer E . erbB-3, a third member of the erbB/epidermal growth factor receptor gene family: its expression in head and neck cancer cell lines. Eur Arch Otorhinolaryngol. 1993; 250(7):392-5. DOI: 10.1007/BF00180383. View

Rajkumar T, Gullick W . A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines. Br J Cancer. 1994; 70(3):459-65. PMC: 2033356. DOI: 10.1038/bjc.1994.328. View

Leary J, EDWARDS B, Houghton C, Kefford R, Friedlander M . Amplification of HER-2/neu oncogene in human ovarian cancer. Int J Gynecol Cancer. 1992; 2(6):291-4. DOI: 10.1046/j.1525-1438.1992.02060291.x. View

Kraus M, Issing W, Miki T, Popescu N, Aaronson S . Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A. 1989; 86(23):9193-7. PMC: 298460. DOI: 10.1073/pnas.86.23.9193. View

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

Lemoine N, Lobresco M, Leung H, Barton C, Hughes C, Prigent S . The erbB-3 gene in human pancreatic cancer. J Pathol. 1992; 168(3):269-73. DOI: 10.1002/path.1711680305. View

10.

Alimandi M, Romano A, Curia M, Muraro R, Fedi P, Aaronson S . Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995; 10(9):1813-21. View

11.

Fan Z, Baselga J, Masui H, Mendelsohn J . Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993; 53(19):4637-42. View

12.

Beerli R, Chen X, Yarden Y, Hynes N . Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol. 1995; 15(12):6496-505. PMC: 230902. DOI: 10.1128/MCB.15.12.6496. View

13.

Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller Jr W . Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993; 85(16):1327-33. DOI: 10.1093/jnci/85.16.1327. View

14.

Guy P, Platko J, Cantley L, Cerione R, Carraway 3rd K . Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A. 1994; 91(17):8132-6. PMC: 44559. DOI: 10.1073/pnas.91.17.8132. View

15.

Sanidas E, FILIPE M, Linehan J, Lemoine N, Gullick W, Rajkumar T . Expression of the c-erbB-3 gene product in gastric cancer. Int J Cancer. 1993; 54(6):935-40. DOI: 10.1002/ijc.2910540612. View

16.

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

17.

Rajkumar T, Gooden C, Lemoine N, Gullick W, Goden C . Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. J Pathol. 1993; 170(3):271-8. DOI: 10.1002/path.1711700309. View

18.

Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R . Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990; 50(13):4087-91. View

19.

Plowman G, Green J, Culouscou J, Carlton G, Rothwell V, Buckley S . Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature. 1993; 366(6454):473-5. DOI: 10.1038/366473a0. View

20.

Hunt C, Hale R, Armstrong C, Rajkumar T, Gullick W, Buckley C . c-erbB-3 proto-oncogene expression in uterine cervical carcinoma. Int J Gynecol Cancer. 1995; 5(4):282-285. DOI: 10.1046/j.1525-1438.1995.05040282.x. View